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Discovering target and off-target effects of
specific compounds is critical to drug discovery
anddevelopment.Wegeneratedacompendium
of ‘‘chemical-genetic interaction’’ profiles by
testing the collection of viable yeast haploid de-
letion mutants for hypersensitivity to 82 com-
pounds and natural product extracts. To cluster
compounds with a similar mode-of-action and
to reveal insights into the cellular pathways
and proteins affected, we applied both a hierar-
chical clustering and a factorgram method,
which allows a gene or compound to be associ-
ated with more than one group. In particular, ta-
moxifen, a breast cancer therapeutic, was found
to disrupt calcium homeostasis and phosphati-
dylserine (PS) was recognized as a target for
papuamide B, a cytotoxic lipopeptide with anti-
HIV activity. Further, the profile of crude ex-
tracts resembled that of its constituent purified
natural product, enabling detailed classification
of extract activity prior to purification. This com-
pendium should serve as a valuable key for in-
terpreting cellular effects of novel compounds
with similar activities.INTRODUCTION
Determining the mode-of-action of new compounds is a
central problem in chemical biology. Rich functional infor-
mation can be obtained from scoring 5000 viable yeast
haploid deletion mutant strains for hypersensitivity to a
diverse set of compounds, a process termed chemical-
genetic profiling (Parsons et al., 2004). Gene deletions
that render cells hypersensitive to a specific drug identify
pathways that buffer the cell against the toxic effects of
the drug and thereby provide clues about its mode-of-ac-
tion (Giaever et al., 2004; Lum et al., 2004; Parsons et al.,
2004). As outlined conceptually for drug-induced changes
in global patterns of gene expression (Hughes et al., 2000;
Marton et al., 1998), an emerging view is that compounds
with similar biological effects lead to similar chemical-
genetic profiles (Brown et al., 2006; Lee et al., 2005). Thus, a
compendium of chemical-genetic profiles should provide
a data set that will both allow for organization of both com-
pounds and yeast genes into functionally relevant groups
and also identify sets of compounds with similar biological
effects and genes whose deletion leads to sensitivity to
similar compound sets. Ultimately, the integration of large-
scale genetic interaction data obtained from genome-
wide synthetic lethal screens (Tong et al., 2001, 2004)
and chemical-genetic data should provide a system for
linking compounds to their target pathway (Parsons
et al., 2004).Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc. 611
Many compounds are in limited supply, and thus a
major challenge is to screen the collection of yeast de-
letion mutants efficiently. Parallel fitness tests of large
numbers of pooled deletion strains in a minimal amount
of medium is possible due to the unique molecular bar-
codes that tag and identify each deletion strain (Giaever
et al., 2002; Shoemaker et al., 1996). Here, we tested 82
chemical perturbations against the yeast haploid dele-
tion collection using parallel fitness tests. Hierarchical
clustering analysis and probabilistic sparse matrix fac-
torization of the compendium of chemical-genetic inter-
action profiles reveals numerous insights into the path-
ways and proteins affected by drug treatments. In
particular, we show that tamoxifen, a breast cancer ther-
apeutic, disrupts calcium homeostasis, and we identify
PS as a target for papuamide B, a cytotoxic cyclic lipo-
peptide with antifungal and anti-HIV activity (Ford et al.,
1999).
RESULTS
A Compendium of Chemical-Genetic Profiles
We generated chemical-genetic profiles for 82 different
conditions by screening them against the yeast haploid
deletion collection. Included in this group are 75 syn-
thetic compounds and natural products, of which 23
are FDA approved, and 7 crude antifungal extracts, de-
rived from different marine sponges and microorganisms.
The list of chemicals, the experimental concentrations,
and a brief comment on their mode-of-action are in-
cluded in Table 1. To mine information from our com-
pendium we applied two data visualization and analysis
techniques to the dataset: two-dimensional hierarchical
clustering and probabilistic sparse matrix factorization
(PSMF) analysis.
Two-Dimensional Hierarchical Clustering Analysis
The set of chemical-genetic profileswas visualizedby two-
dimensional hierarchical clustering (Figure 1). This data
matrix contains all chemical-genetic interactions where
the combined average log2 ratio (control/experiment) of
both barcodes (uptag and downtag) corresponding to
each strain is greater than 0.5,meaning that the drug treat-
ment leads to at least a 1.4-fold depletion of the deletion
mutant relative to the control. Prior to clustering, we pro-
cessed the data by removing a set of 121 genes whose
corresponding deletion mutant displayed statistically sig-
nificant multidrug sensitivity (Table S2). This multidrug-
resistant gene set includes genes whose deletion leads
to increased membrane permeability, including ERG2,
ERG5, and ERG6, as well as PDR5, which encodes
a drug-efflux pump, and PDR1, encoding a transcription
factor that regulates genes involved in multidrug resis-
tance. In total, 82 conditions were clustered on the vertical
axis, based upon the overlap of their chemical-genetic
profiles, and 3418 genes were clustered on the horizontal
axis, according to their overlapping patterns of compound
sensitivities.612 Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc.Clustering Chemical-Genetic Profiles for
Compounds with Similar Modes-of-Action
and Genes with Similar Function
We found that compounds with similar cellular effects
showed similar chemical-genetic profiles and thereby
cluster together on the vertical axis in Figure 1, revealing
both anticipated and novel insights into their mode-of-
action. In particular, there are a number of examples
where the cluster analysis groups compounds known to
inhibit the same pathway or target (Figure 1, individual
clusters indicated by roman numerals): (i) actin binding
agents latrunculin B (Ayscough et al., 1997) and cytochala-
sin A (Torralba et al., 1998); (ii) cell wall synthesis inhibitors
staurosporine, which targets Protein kinase C, a regulator
of a MAP kinase cascade involved in cell wall metabolism
(Yoshida et al., 1992), and caspofungin, which inhibits 1,3
b-glucan synthase (Douglas et al., 1994b); (iii) nystatin
(Hosono, 2000) and amphotericin (Aoun, 2000), both of
which act by increasing the permeability of the fungal cell
membrane; (iv) clotrimazole and fluconazole, chemical
analogs andantifungal agents that target Erg11 (Fromtling,
1988; Truan et al., 1994), a protein encoded by an essential
gene in the ergosterol biosynthesis pathway; (v) radicicol
and geldanamycin, although structurally unrelated, both
act as highly selective inhibitors of Hsp90 function through
their ability to bind within the ADP/ATP binding pocket of
the chaperone (Roe et al., 1999); (vi) benomyl (Thomas
et al., 1985) and nocodazole (Kunkel, 1980), two microtu-
bule poisons; (vii) haloperidol (Moebius et al., 1996), feni-
propimorph (Marcireau et al., 1990), and dyclonine
(Hughes et al., 2000), are all thought to inhibit Erg2 function
in yeast. Deletion mutants with similar chemical sensitiv-
ities also cluster together on the horizontal axis of Figure 1,
grouping functionally related genes (Figure S1).
Probabilistic Sparse Matrix Factorization Analysis
Two-dimensional hierarchical clustering is limited by its in-
ability to associate a gene or compound with more than
one group. In order to discover links between compound
activities that may not be revealed by hierarchical cluster-
ing, we used probabilistic sparse matrix factorization
(PSMF) (Dueck et al., 2005). In hierarchical clustering,
each mutant has a chemical sensitivity signature in re-
sponse to a set of compounds, and mutants are linked to-
gether based on a comparison of all compounds. In a fac-
torization analysis, chemical sensitivity signatures are
linked together based on a variety of subsets of com-
pounds. This allows the same mutant to be linked to
multiple other mutants based on different subsets of com-
pounds. Each compound in the subset can have a different
importance and different subsets can overlap. We refer
to each subset of compounds detected by the algorithm
as a factor. Each mutant’s sensitivity signature can be
represented as a weighted sum of factors.
Techniques other than PSMF can be used to factorize
matrix data; however, PSMF has been previously applied
tomicroarray data, where it was shown to achieve a higher
rate of significant clusters/factors discovery compared to
Table 1. Chemicals and Natural Product Extracts Screened in This Study
Compound
Inhibitory
Concentration Comments
()-Abietic acid 0.33 mM major component of oleoresin synthesized by conifer species, inhibits
lipoxygenase activity
(+/) Coniine 5% (v/v) poisonous teratogenic piperidine alkaloid
(+)-Usnic acid 61 mM dibenzofuran derivative, various biological activities (i.e., antibiotic,
anti-inflammatory)
(1R, 2S, 5R) - () - Menthol 480 mM terpene alcohol used as a flavoring
(S)-(+)-Camptothecin 30 mM topoisomerase I inhibitor
1-10 Phenanthroline monohydrate 0.02 mM metal chelator that inhibits Pol II by sequestering magnesium
2-Hydroxyethilhidrazine 5% (v/v) inhibits the phospholipid methylation in yeast
4-Hydroxytamoxifen 36.1 mM metabolite of tamoxifen
Actinomycin D 37 mM binds to DNA and inhibits RNA synthesis
Agelasine E 0.03 mM unknown target
Alamethicina 59.3 mM cyclic nonadecapeptide antibiotic that can act as an ionophore
Amantadine hydrochloride 5.9 mM polycyclic cage compound with antiviral and anti-Parkinsonian activities
Amiodarone hydrochloride 150 mM antianginal and antiarrhythmic drug
Amphotericin B 0.76 mM compromises cell membrane integrity
Anisomycin 3.8 mM protein synthesis inhibitor, inhibits peptidyl transferase in
eukaryote ribosomes
Artemisinin 88.5 mM antimalarial sesquiterpene lactone, inhibits the SERCA ortholog
of Plasmodium falciparum
Basiliskamide 0.26 mM unknown target
Benomyl 0.12 mM Microtubule-depolymerizing agent
Brefeldin A 0.36 mM secretory pathway inhibitor
Caffeine 3.1 mM phosphodiesterase inhibitor
Calcium ionophore A23187 191 mM calcium ionophore
Caspofungin 7 nM inhibits synthesis of glucan, a component of the yeast cell wall
Cerulenin 1.6 mM inhibits the elongation of fatty acids
Chlorpromazine hydrochloride 28.2 mM prototypical phenothiazine antipsychotic drug
Cisplatin 0.17 mM DNA inter- and intracross linking agent
Clomiphene citrate 4.9 mM stilbene derivative structurally related to chlorotrianisene
Clotrimazole 0.4 nM inhibitor of ergosterol biosynthesis in yeast
Cyclopiazonic acid 0.4 mM sarcoplasmic reticulum Ca2+- ATPase inhibitor
Cytochalasin A 21 mM inhibits actin polymerization
Desipramine hydrochloride 231 mM used to treat depression and other mood disorders
Doxycycline hyclate 1.12 mM antibiotic
Dyclonine hydrochloride 55.2 mM local anaesthesic, inhibits the ergosterol pathway
Emetine dihydrochloride hydrate 1.25 mM protein synthesis inhibitor
Emodin 0.4 mM casein kinase II inhibitor
Extract 00-132 32 mg/ml antifungal natural product extract
Extract 00-192 15 mg/ml antifungal natural product extract
Extract 00-243 10 mg/ml antifungal natural product extract
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Table 1. Continued
Compound
Inhibitory
Concentration Comments
Extract 00-303C 29 mg/ml antifungal natural product extract
Extract 00-89 5 mg/ml antifungal natural product extract
Extract 6592 130 mg/ml antifungal natural product extract
Extract 95-57 30 mg/ml antifungal natural product extract
Fenpropimorph 0.00001%(v/v) morpholine fungicide used in agriculture, inhibits sterol isomerase
and sterol reductase
FK506 9 nM immunosuppressant drug, inhibits calcinuerin function in yeast
Fluconazole 0.03 mM inhibitor of ergosterol biosynthesis in yeast
Geldanamycin 36 nM HSP90 inhibitor
Haloperidol 0.1 mM a butyrophenone antipsychotic drug used to treat schizophrenia,
binds the sigma receptor
Harmine hydrochloride 241.2 mM b-carboline alkaloid, cytotoxic activities against human tumor cell lines
Hoechst 33258 93.7 mM DNA minor groove binding agent
Hydrogen peroxide 0.4%(v/v) oxidizing agent
Hydroxyurea 20 mM DNA-damaging agent, inhibits ribonuclease reductase
Hygromycin B 8 nM aminoglycoside antibiotic
Latrunculin B 30 mM actin-depolymerizing agent
LY 294002 hydrochloride 290 mM mammalian PI3 kinase inhibitor
Methanesulfonic acid methyl
ester (MMS)
0.004% DNA-alkylating agent
Mitomycin C 0.15 mM DNA-damaging agent
Neomycin B trisulfate salt hydrate 150 mM aminoglycoside antibiotic, inhibits ribozyme function
Nigericin 69 mM polyether antibiotic and ionophore
Nocodazole 10 mM Microtubule-depolymerizing agent
Nystatin dihydrate 0.7 mM compromises cell membrane integrity
Oligomycinb 127 mM inhibits membrane bound mitochondrial ATPase
Papuamide B 0.4 mM natural product of unknown target
Parthenolide 141 mM sesquiterpene lactone with anti-inflammatory properties
Pentamidine isethionate 130 mM antiprotozoal agent
Phenylarsine oxide 8 mM phosphatidylinositol 4-kinase inhibitor
Plumbagin 4.2 mM naphtaquinone derivative that induces cell death through generation
of reactive oxygen species
Radicicol 49.3 mM macrolactone protein tyrosine kinase inhbitor; HSP90 inhibitor
Raloxifene hydrochloride 1.05 mM estrogen antagonist
Rapamycin 5.5 pM inhibitor of TOR kinase signaling
Sodium azide 77 mM cytochrome oxidase inhibitor
Staurosporine 3 mM PKC inhibitor
Stichloroside 1 nM unknown target, active compound from extract 00-192
Sulfometuron methyl 0.2 nM inhibitor of amino acid biosynthesis
Tamoxifen 5.4 mM competitively inhibits estradiol binding to estrogen receptor
Theopalauamide 0.4 nM unknown target, active compound from extract 00-132
Thialysine 3 mM toxic lysine analog614 Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc.
Table 1. Continued
Compound
Inhibitory
Concentration Comments
Trichostatin A 99.2 mM histone deacetylase inhibitor
Trifluoroperazine dihydrochloride 11 mM phenothiazine with actions similar to chlorpromazine
Tunicamycin 71 pM inhibitor of protein glycosylation
U-73122 0.2 mM phospholiapse C inhibitor
Valinomycin 2.2 mM potassium selective ionophore
Verrucarin 2 mM macrocyclic trichothecene; protein synthesis inhibitor
Wortmannin 0.3 nM inhibitor of phosphatidylinositol kinase signalling
NA: Not applicable.
Inhibitory concentration refers to the screening concentration. Complete table including CAS numbers, FDA status, source, site of
collection, and references in Table S1.
aA mixture of alamethicin analogs.
bA mixture of oligomycins A, B, and C.hierarchical clustering or other factorization techniques,
including principal and independent components analysis
(Dueck et al., 2005). A particular advantage of PSMF over
another multiway factorizating technique, bi-clustering
(Cheng and Church, 2000), is that PSMF allows each clus-
ter to be defined by an arbitrary set of genes and com-
pounds, whereas bi-clustering is restricted so that any
two clusters containing the same gene (or compound)
must be defined by exactly the same set of genes (or com-
pounds). In related work, variational inference in a labeled
latent Dirichlet allocation process was used to analyze
chemical-genetic profiles (Flaherty et al., 2005), but this
analysis employed prior knowledge of gene functions
(MIPS annotations), whereas our PSMF analysis alto-
gether avoids the need for gene function annotations.
In this analysis, we identified 30 factors and represented
each signature as aweighted sumof up to three factors. By
detecting a factor, the algorithm is identifying compounds
that have a similar effect on a specific group of mutants.
The factors can correlate to different cellular functions; for
example, compounds that inhibit DNAsynthesis and repair
may form one factor because a group of mutants sensitive
to those compounds display similar sensitivity. Thus, the
factorization approach gives a complete representation
of groups of related compounds that affect groups of re-
lated mutants, while allowing for each mutant and each
compound to be linked to more than one cellular function.
The ‘‘factorgram’’ (Cheung et al., 2006) shown in
Figure 2 is a visualization of the factorization results as
applied to the compendium of chemical-genetic profiles.
Each factor is visually represented by a block of data
showing the original data matrix entries for the subset of
the compounds in that factor, and the subset of mutants
which are most significantly affected by the given factor.
The factors are shown along the diagonal of Figure 2.
Four detailed examples of factors and the subsets of
strains utilizing specific factors are shown in Figures 2A–
2D. The group of compounds present in the factor is listed
along the x axis, with themost important compound on theleft. Along the y axis are strains using that factor, with the
most significant strain at the top. For example, in Fig-
ure 2A, papuamide B and alamethicin are the compounds
that are most important in factor number 5, and this is
driven by the common sensitivity of the deletion mutants
listed on the y axis, with the most significant mutants at
the top (hoc1D, pps1D, ypl158cD, and so on).
One group that emerged from the PSMF analysis is that
of the DNA-damaging agents, linking together in factor
21, as expected, the similar activities of mitomycin C,
MMS, camptothecin, cisplatin, and hydroxyurea (Fig-
ure 2B). However, an additional component of that factor
is actinomycin, an antibiotic that binds to DNA and inhibits
RNA synthesis (Sobell, 1985). Interestingly, this com-
pound does not cluster next to the DNA-damage agents
in Figure 1 but instead clusters virtually on its own. The
mutants defined by this profile (includingTOP3, MUS81,
andRAD52; i.e., the deletionmutants which are hypersen-
sitive to camptothecin) are enriched for lesions in DNA
replication and repair.
In a second example, verrucarin and neomycin sulfate
are two compounds linked by PSMF analysis (factor 6;
Figure 2C) and not by hierarchical clustering. Verrucarin
inhibits protein synthesis in yeast (Hernandez and Can-
non, 1982) and neomycin sulfate is an aminoglycoside an-
tibiotic that inhibits protein translation (Schroeder et al.,
2000). The deletion mutants utilizing that factor include
many cytoplasmic ribosomal small subunit deletion mu-
tants and translation initiation factors, in accordance to
the mode-of-action of the compounds.
Chemical-Genetic Profiling of Crude Extracts
Containing Bioactive Natural Products
Because chemical-genetic profiling is applicable to any
compound that impairs yeast cell growth, it can also be
applied to natural product extracts, which appear to often
contain only one growth-inhibitory compound. To test
whether chemical-genetic profiling may be particularly
useful for classifying natural product extracts prior toCell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc. 615
Figure 1. Two-Dimensional Hierarchical
Clustering Analysis of Chemical-Genetic
Profiles
Eighty-two conditions, including 75 com-
pounds and 7 crude extracts, were clustered.
3418 genes are plotted on the horizontal axis
with the gene cluster tree above. Compounds
are plotted on the vertical axis with the cluster
tree on the outermost right side of the plot.
Chemical-genetic interactions are represented
as red lines. Compound clusters are labeled
with roman numerals as referenced in the text.embarking on the time-consuming purification of the ac-
tive component, we examined the profiles of 7 different
antifungal extracts derived from marine sponges and mi-
croorganisms. Surprisingly, two of the extracts derived
from different organisms and diverse locations, extract
00-192, from a sea cucumber from the Commonwealth
of Dominica and extract 00-132, derived from an Indone-
sian marine sponge, showed highly similar chemical-ge-
netic profiles, resembling the reproducibility we observe
for repeated screens of the same compound (Figure 3A).
Moreover, they clustered together within the compendium
(Figure 1, cluster x) andwere linked by PMSF analysis (fac-
tor 29; Figure 2D). Thus, the two extracts appear to con-
tain antifungal compounds with similar modes of action.
We purified antifungal compounds from the two crude
extracts. The compound isolated from extract 00-192616 Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc.was identical to stichloroside (Kitagawa et al., 1981),
whereas the compound isolated from extract 00-132
was identical to theopalauamide (Schmidt et al., 1998).
Both of the purified compounds display chemical-genetic
profiles resembling those of their crude extracts (Figure 1,
cluster x), confirming that these compounds are responsi-
ble for the antifungal activity within the extracts. The two
compounds do not share structural features and thus
chemical-genetic profiling appears to have linked mole-
cules with disparate chemistry to the same biological
activity (Figure 3B).
Drug-resistant mutants often result from mutations in
the target gene or pathway (Douglas et al., 1994b; Fried
and Warner, 1982; Heitman et al., 1991). To obtain further
evidence for a similar mode-of-action between the two
compounds, we isolated stichloroside-resistant mutants
Figure 2. Visualization of Results from PSMF
Each numbered block along the diagonal shows the data that contributed to a particular factor and displays the mutants and compounds discovered
by PSMF. The statistically significant mutants utilizing each factor are shown along the vertical axis and are sorted according to the weighting of the
factor in explaining the chemical-sensitivity profile for the mutant. The subset of compounds significantly present in each factor are shown along
the horizontal axis and are sorted according to their importance within the factor. Compounds and strains may appear several times. Color bar on
the left indicates the scale of the normalized data (see Experimental Procedures). An expanded view of several blocks are detailed: (A) factor number
5, (B) factor 21, (C) factor 6, (D) factor 29. Each expanded view shows the 8 most important compounds and the 30 most significant mutants.and then tested the mutants for theopalauamide resis-
tance. Four independent strains were isolated as resistant
to extract 00-192 and were subsequently confirmed to be
resistant to its active compound, stichloroside. For each
of the four strains, the resistance was attributable to a
single recessive mutation, and the mutants fell into two
complementation groups (00-192-RA and 00-192-RB). If
stichloroside and theopalauamide function similarly, the
stichloroside-resistant mutants should also display theo-
palauamide resistance, and indeed we found this to be
true (Figure 3C). The identities of the genes affected by
the mutations conferring the drug resistance are not
known, but neither is linked to PDR1 or PDR3, two genes
involved in general multidrug resistance. In addition, the
resistant phenotype is specific because the mutants dis-
played wild-type sensitivity to cycloheximide, caspofun-
gin, and papuamide B (data not shown). We conclude that
stichloroside and theopalauamide share acommonmode-
of-action in yeast and that chemical-genetic profiling isan effective means for functional classification of natural
product extracts.
Compendium Reveals Insights into the Activities
of Human Therapeutics
Interestingly, the chemical-genetic interaction profile of
amiodarone, an antianginal and antiarrhythmic drug, clus-
ters with tamoxifen, a competitive inhibitor of estradiol
binding to the estrogen receptor and a common breast
cancer drug (Figure 1, cluster ix). The antifungal activity
of amiodarone appears to be related to its mode-of-action
in human cells and is associated with the perturbation of
calcium homeostasis, resulting in an increase in cytosolic
Ca2+ to toxic levels through an influx of external Ca2+ and
release of internal Ca2+ stores into the cytosol upon drug
exposure (Courchesne, 2002; Courchesne and Ozturk,
2003; Gupta et al., 2003). The resemblance of the chemi-
cal-genetic profiles of amiodarone and tamoxifen indi-
cates that the physiological effects of these drugs onCell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc. 617
Figure 3. Chemical-Genetic Analysis of Natural Product Extracts
(A) Correlation plot between chemical-genetic screens of extract 00-132, derived from a marine sponge collected in Indonesia, and extract 00-192,
derived from a sea cucumber collected in the Dominican Republic (correlation coefficient (r) = 0.892). Points on the plot correspond to the log2 ratio
of control signal/drug-treated signal for each barcode in the two screens. For comparison purposes, a correlation plot showing two pap B screens
at similar concentrations (0.8 and 0.7 mg/ml; r = 0.953) is shown as well as a plot depicting two different chemical treatments (extract 00-192 and
amiodarone; r = 0.533).
(B) Structures of stichloroside and theopalauamide. Stichloroside is the active compound derived from crude extract 00-192 and theopaluamide is the
active compound present in crude extract 00-132.
(C) Cross-resistance of extract 00-192 resistant strains 00-192-RA and 00-192-RB to 4 mg/ml stichloroside and 1 mg/ml theopaluamide.618 Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc.
Figure 4. Activation of the Calcineurin/
Crz1-Signaling Pathway by Amiodarone
and Tamoxifen
(A) Microarray profiling shows the induction of
Crz1-regulated gene expression upon drug
exposure and overproduction of Crz1. The
Crz1-regulated gene list is from Yoshimoto
et al. (Yoshimoto et al., 2002). The CRZ1 over-
expression strain (CRZ1OE) that contains a
Crz1-GST fusion under control of the GAL1-
10 promoter was induced for 3 hr with 2%
galactose.
(B) A LacZ reporter driven by the calcineurin-
dependent response element (CDRE) is acti-
vated by drug treatment.
(C) GFP-Crz1 is translocated into the nucleus
within 10 min of drug exposure in amiodarone-
and tamoxifen-treated cells. Approximately
1000 cells were counted for nuclear (N), cyto-
plasic (C), or intermediate (I) localization of
GFP-Crz1. Values are the average of three rep-
licate experiments and reported as%N:%C:%I
where the error (in parentheses) is the largest
difference from the average over the three
experiments.
(D) Chemical structures of amiodarone and
tamoxifen.yeast cells may be similar, suggesting that tamoxifen may
also produce an increase in cytosolic Ca2+ in yeast. To test
this possibility, we assayed for the activation of the Ca2+/
calcineurin/Crz1 signaling pathway in both drug treat-
ments. In response to high concentrations of external
Ca2+, calcineurin induces the transcription of genes re-
quired for the cell’s adaptation to calcium stress by pro-
moting the nuclear translocation of the transcription
factor Crz1. Crz1 subsequently binds to the calcineurin-
dependent response element (CDRE) within the promoter
regions of the stress-response genes (Matheos et al.,
1997; Stathopoulos and Cyert, 1997; Stathopoulos-
Gerontides et al., 1999; Yoshimoto et al., 2002). Indeed,
both tamoxifen and amiodarone treatments activate the
Ca2+/calcineurin/Crz1 signaling pathway, as shown in
three independent assays: (1) microarray profiling reveals
the induction of Crz1-regulated gene expression upon
drug exposure; (2) a LacZ reporter driven by the calci-neurin-dependent response element (CDRE) is activated
by drug treatment; (3) Crz1 is translocated into the nucleus
within 10 min after drug exposure (Figures 4A–4C). The
CDRE-lacZ reporter is activated to a greater extent by
amiodarone as compared to tamoxifen (Figure 4B) and
similarly, amiodarone treatment leads to greater nuclear
localization of GFP-Crz1 than tamoxifen (Figure 4C), sug-
gesting that amiodarone is a more potent activator of cal-
cineurin signaling.We also note that, as assessed byGFP-
Crz1 localization, tamoxifen appears to be a more potent
activator of calcineurin signaling than amantadine and
other compounds that cluster near amiodarone and ta-
moxifen in Figure 1 (Figure S2). Strikingly, tamoxifen and
amiodarone share structural similarities (Figure 4D).
Thus, our analysis suggests that tamoxifen and amiodar-
one may be affecting similar pathways in yeast, implying
that some of their biological effectsmay be due to overlap-
ping cellular targets in humans as well. Indeed, there isCell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc. 619
Figure 5. Papuamide B
(A) Cyclic lipopeptide structure of pap B.
(B) Spot dilution assays depicting sensitivity
and resistance of various mutants to pap B.
cho1D strains cannot synthesize phosphatidyl-
serine (PS) and strains lacking DNF1, DNF2,
and/or DRS2 are defective for flipping PS
from the outer bilayer of the cell membrane
to the inner bilayer, resulting in an excess of
PS in the outer membrane. cho1D and
cho1Ddrs2D strains are resistant to 4 mg/ml
pap B whereas drs2D, dnf1Ddnf2D, and
dnf1Ddnf2Ddrs2D strains are hypersensitive
to 2 mg/ml pap B.
(C) Pap B permeabilizes liposomes containing
PS. Release of calcein, a fluorescent marker
from 100% PC, 90% PC/10% PE, and 90%
PC/10% PS liposomes over a series of paua-
mide B concentrations was quantified com-
pared to 100% release from liposomes ex-
posed to Triton-X 100. Pap B is approximately
100-fold more potent against PC liposomes
with 10% PS than PC liposomes or PC lipo-
somes with 10% PE. Data correspond to the
mean values of at least four experiments. Error
bars correspond to the standard deviation.evidence that tamoxifen causes an increase in intracellular
free Ca2+ concentrations in a number of cell types includ-
ing renal tubular cells (Jan et al., 2000), breast cells (Chang
et al., 2001, 2002), bladder cells (Chang et al., 2001), and
Chinese hamster ovary cells (Jan et al., 2003). These non-
estrogen receptor-mediated effects cause cytotoxicity
at tamoxifen concentrations that are higher than those
normally used in the clinic (106M) (Jain and Trump, 1997).
Linking Papuamide B to Its Cellular Target,
Phosphatidylserine
Papuamide B (pap B), a high-molecular-weight cyclic-
lipopeptide originally isolated from a marine sponge, is
a cytotoxic compound with anti-HIV activity (Figure 5A)
(Ford et al., 1999). Pap B also has potent antifungal activity
with an MIC (minimal inhibitory concentration) against620 Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc.S. cerevisiae of less than 1 mg/ml (data not shown). The
chemical-genetic profile of pap B includes over 300 genes
with a log2 ratio of greater than 1.58, representing a 3-fold
or greater underrepresentation of the corresponding dele-
tion strain in the drug treated versus non-drug-treated
pool. To identify the top strains that were specifically
hypersensitive to individual compounds, we assigned
a p value to each chemical-genetic interaction based on
a modified Student’s t test. This method better highlights
chemical-genetic interactions specific to the compound
and puts less emphasis onmore promiscuous interactions
(Lum et al., 2004). The top 50 pap B hits sorted by p value
are listed in Table S3 (assigned p values for our complete
data set are listed in Table S4). The pap B list is enriched
for genes with certain Gene Ontology annotations includ-
ing vesicle-mediated transport (p = 0.0002958), cell-wall
organization and biogenesis (p = 1.115e-10), and protein
modification (p = 0.0003363), suggesting that this com-
pound may affect intracellular transport or perturb some
target on the cell surface (Robinson et al., 2002). In addi-
tion, we compared the pap B chemical-genetic screen
to a set of 132 genome-wide genetic interaction screens
(Tong et al., 2004) by hierarchical clustering and found
that the pap B screen clustered with genetic screens of
cell-surface mutants (Figure S3).
Molecular analysis of several different vesicular traffick-
ing pathways failed to reveal a pap B-specific effect (Fig-
ure S4). Because the most recent antifungal drug, caspo-
fungin (Kartsonis et al., 2003), is also a cyclic lipopeptide
and it is known to target the yeast cell wall (1-3) b-glucan
synthase (Douglas et al., 1994a, 1994b), we tested if pap
B perturbed (1-3) b-glucan synthase activity in vitro; how-
ever, we observed no effect of pap B in this assay (Fig-
ure S5), suggesting that it interacts with a novel cell-
surface target.
Because specific drug targets can often be identified
through the analysis of drug-resistant mutants (Douglas
et al., 1994a, 1994b; Fried and Warner, 1982; Heitman
et al., 1991), we isolated pap B-resistant mutants by spot-
ting wild-type cells on rich medium containing high con-
centrations of pap B. Genetic analysis confirmed that
the resistance was associated with a single complemen-
tation group and identified a single gene. In addition, we
found that the resistant mutant was unable to grow on
minimal medium, which enabled us to clone the gene as-
sociated with resistance by using a plasmid-based geno-
mic library to complement the minimal medium growth
defect. We cloned theCHO1 gene and, through sequence
and subsequent genetic analysis, identified the drug-
resistant strain as a cho1 null mutant.
CHO1 encodes a nonessential enzyme required for the
synthesis of PS (Kiyono et al., 1987), one of four major
phospholipids that comprise S. cerevisiae cell mem-
branes. In the eukaryotic plasmamembrane, sphingolipids
and phosphotidylcholine (PC) are mainly located in the
outer leaflet of the plasma membrane whereas PS and
phosphatidylethanolamine (PE) are mainly located in the
inner leaflet. This asymmetry is established by aminophos-
pholipid translocases that ‘‘flip’’ PS and PE from the outer
leaflet to the inner leaflet. Potential aminophospholipid
translocases in yeast include Drs2, Dnf1, and Dnf2 (Natar-
ajan et al., 2004; Pomorski et al., 2003); consequently,
drs2D, dnf1D, and dnf2D expose more PS on the outer
leaflet of the cell membrane than wild-type cells. If pap B
interacts with PS and if this interaction is important for
its antifungal activity, then mutants defective for amino-
phospholipid translocases should be hypersensitive to
pap B. Indeed, we found that drs2D, dnf1Ddnf2D, and
drs2Ddnf1Ddnf2D cells were hypersensitive to pap B, in
contrast to the cho1D cells which are resistant to pap B
(Figure 5B). In addition, ten deletion strains with high log2
ratios in thepapBscreenwere assayed for annexin Vbind-
ing, a PS-specific protein (van Engeland et al., 1998).
These mutants bound more annexin V than wild-type cells(Figure S6), suggesting that likedrs2D, thesemutants have
excess PS on the outer leaflet of their cell membrane,
which results in their sensitivity to pap B.
The potential interaction of pap B with PS suggests that
the antifungal activity of pap Bmay result from its ability to
bind PS on the plasma membrane and thereby disrupt
membrane integrity, leading to inappropriate permeability.
To examine this possibility using chemical-genetic profil-
ing, we analyzed a general antimicrobial pore-forming
peptide, alamethicin (Bechinger, 1997). If pap B disrupts
membrane permeability, then alamethicin and pap B
should show similar chemical-genetic profiles. Indeed,
we found that pap B and alamethicin cluster together
within the compendium (Figure 1, cluster xi) and were
also associated together using PMSF analysis (factor pro-
file 5, Figure 2A). Moreover, we also found that the chem-
ical-genetic profile of Ro 09-0198, a peptide that binds PE,
inducing transbilayer lipid movement and compromising
cell membrane integrity (Makino et al., 2003), also clusters
with pap B and alamethicin (Figure S7).
To further test the hypothesis, we studied the effect of
pap B on marker release from liposomes containing PS.
Strikingly, pap B is about 100-fold more potent against
PC liposomes with 10% PS than PC liposomes with
10% PE. Pure PC liposomes were only slightly permeabi-
lized at the highest concentration of pap B tested (Fig-
ure 5C). Taken together, these lines of evidence support
a mechanism of action for pap B in which it compromises
yeast cell membrane integrity through a direct interaction
with PS. Interestingly, there is evidence that PS in the
outer leaflet of the HIV-1 membrane is required for HIV
infection (Callahan et al., 2003), and the PS-specific pro-
tein annexin V specifically inhibits HIV infection presum-
ably through its interaction with PS (Callahan et al.,
2003), suggesting a similar mechanism for the anti-HIV
activity of pap B.
DISCUSSION
Here, we tested the set of yeast viable deletion mutants
for hypersensitivity to growth-inhibitory compounds and
generated a compendium of chemical-genetic profiles de-
rived from compounds targeted to a number of distinct
cellular pathways and functions, including the actin cyto-
skeleton, the cell wall and cell membrane, ergosterol bio-
synthesis, the microtubule cytoskeleton, hsp90 chaper-
one function, protein synthesis and translation, and DNA
metabolism. Hierarchical clustering analysis and probabi-
listic sparse matrix factorization identified similarities
between chemical-genetic profiles that often reflect a
common biological target or mode-of-action. Thus, this
compendium should provide a valuable key for interpret-
ing the cellular effects of novel compoundswith similar ac-
tivities. The continued expansion of the compendium will
generate amore sophisticated resource for highly detailed
functional classification of compounds, grouping com-
pounds that perturb similar sets of gene deletion mutants,Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc. 621
and genes, identifying sets of deletion mutants that show
sensitivity to similar sets of compounds.
Barcode-based chemical-genetic profiling in yeast is
relatively simple and robust and is broadly applicable to
any compound with growth-inhibitory antifungal activity.
We have shown that it works well with both crude natural
product extracts as well as purified compounds. A com-
pendium approach to chemical-genetic profiling expands
upon the use of haploinsufficiency profiling (HIP) to define
compound mode-of-action. In contrast to chemical-ge-
netic profiling of haploid deletion mutants, which often
identifies tens to hundreds of deletion mutant hypersensi-
tive strains, the HIP assay generally identifies a relatively
small number of potential target genes, often fewer than
10, whose decreased dosage leads to compound hyper-
sensitivity (Baetz et al., 2004; Giaever et al., 1999, 2004;
Lum et al., 2004). Thus, while the HIP assay has the poten-
tial to identify the target gene, there is less functional infor-
mation associated with the mutant hypersensitivity signa-
ture and thus the two approaches are complementary.
Applying chemical-genetic profiling in concert with drug-
resistant mutant analysis, we were able to establish a
cell-surface phospholipid target for a previously unchar-
acterized antifungal compound, papuamide B, whereas
similar conclusions could not be drawn from the HIP assay
mutant hypersensitivity signature (data not shown).
Because a deletion mutant provides a model for the
effect of a compound that inhibits the gene product (Mar-
ton et al., 1998), genetic interaction information obtained
from genome-wide synthetic lethal screens of haploid de-
letion mutants provides a key for interpreting chemical-
genetic profiles and thereby links compounds to their
target pathways based on chemical-genetic interaction
data alone (Parsons et al., 2004). Chemical-genetic profil-
ing is highly sensitive partly because of the quantitative
nature of fitness tests associated with a barcode readout.
Synthetic lethal genetic analysis can also be scored with
a quantitative assessment of double mutant phenotypes,
either through computational analysis of array images
(Schuldiner et al., 2005; Tong et al., 2004) or through a bar-
code microarray readout (Pan et al., 2004). Currently, we
have only cataloged 2%–4% of all genetic interactions
(Tong et al., 2001, 2004) and so our ability to integrate
chemical-genetic and genetic interaction data is limited;
however, large-scale application of genetic interaction
screening should ultimately provide a detailed key for in-
terpretation of chemical-genetic profiles, such as those
described here.
EXPERIMENTAL PROCEDURES
Chemical-Genetic Profiling
Compounds were purchased from Sigma, except for mitomycin C,
radicicol, FK506, cytochalasin, brefeldin A, and camptothecin, which
were purchased from AG Scientific; Hoechst 3358, which was pur-
chased fromMolecular Probes; fenpropimorph, which was purchased
fromReidel; andU73122, whichwas purchased fromCalbiochem. Flu-
conazole was a gift from J. Anderson, geldanamycin was a gift fromW.
Houry, and caspofungin was a gift from G. Giaever. Natural product622 Cell 126, 611–625, August 11, 2006 ª2006 Elsevier Inc.extracts, pap B, agelasine E, and basiliskamide Awere from the collec-
tion of R. Andersen. Compounds were dissolved in DMSO except as
noted: trifluoroperaine, pentamidine, nystatin, MMS, mitomycin C, hy-
gromycin B, hydroxyurea, hydroxyethilhidrazine, hydrogen peroxide,
fluconazole, emetine, doxycycline, caffeine, anisomycin, actinomycin,
thialysin, sodium azide, and clomiphene were dissolved in water; phe-
nantroline, brefeldin A, and artemisinin were dissolved in ethanol; wort-
mannin was dissolved in methanol; cisplatin was dissolved in a 0.9%
sodium chloride solution. Crude extracts were dissolved in methanol.
Chemical-genetic profiling was performed as described (Zhao et al.,
2005). For details see Supplemental Experimental Procedures.
Data Preprocessing
For information on data preprocessing, see Supplemental Experimen-
tal Procedures.
Clustering Analysis
In each experiment, log2 ratios of the control divided by sample inten-
sities were computed for each tag. Log2 ratio measurements of up and
down tags were averaged, when both were available. In the case
where there was only one tag, its value was averaged with the most
probable value for a log2 ratio measurement (approximately zero), ef-
fectively weighing down the impact a measurement from a single tag
may contribute to the analysis, when the other tag is missing. Two-di-
mensional hierarchical agglomerative clustering using Pearson’s cor-
relation and average linkage was applied to the data using Matlab 7
(The MathWorks). Log2 ratios below 0.5 were set to 0, and only those
strains with at least onemeasurement above 0.5 are shown in the clus-
togram. Multidrug-sensitive strains were removed from the analysis
(see below). For the original data set used to generate the cluster
see Table S7 and for the complete clustered data set see Table S8.
Identification of Multidrug-Sensitive Strains
The probability of observing by chance for any given strain as many
log2 ratio measurements above 1.8 as were actually observed was es-
timated using a hypergeometric distribution (Supplemental Experi-
mental Procedures). A set of commonly resistant strains were also
identified (Table S9). Many of these strains have been previously iden-
tified as slowly growing diploid homozygous deletion mutant strains
(Deutschbauer et al., 2005). In our experiments, we run the control
and drug-treated experiments for the same amount of time, such
that the control pool undergoes more population doublings than the
drug-treated (growth-inhibited) pool. As a result, slowly growing
strains may appear relatively enriched, and therefore resistant, in the
drug-treated pool compared to the control.
Analysis of Individual Strain Sensitivity
To assess the significance of the effect of a drug on a deletion strain,
a t test score and a corresponding p value were calculated based on
the log2 ratio measurements of growth of that strain in the presence
of that particular drug, with respect to all othermeasurements obtained
for that strain under all 82 conditions (Lum et al., 2004). For calculation
details see Supplemental Experimental Procedures.
PSMF Analysis
The data were analyzed using probabilistic sparse matrix factorization
(Dueck et al., 2005; Software available at http://www.psi.toronto.ca/
factorgram) applied to a data matrix X of 4111 deletion mutant strains
by 82 compounds, containing all chemical-genetic interactions after
removal of nonfunctional tags, multidrug-sensitive strains, and strains
that do not appear in ORF gene ontology list fromSGD (Table S6). Neg-
ative scores were set to 0. For further details regarding this analysis,
see Supplemental Experimental Procedures. The figure was produced
using a factorgram visualization tool (Cheung et al., 2006), available at
the above website.
Microarray Profiling
Untreated wild-type cells BY4743 (all strain genotypes are listed in the
Supplemental Experimental Procedures) were logarithmically grown in
parallel with cultures treated with DMSO (0.2%), tamoxifen (20 mg/ml),
and amiodarone (200 mg/ml) for 1.5 hr. For the overexpression of
CRZ1, strains containing a 2m-based plasmid encoding aCrz1-GST fu-
sion driven by the GAL1-10 promoter or an empty vector control
(pEGH) were grown concurrently in selective media supplemented
with 2% raffinose to mid-log phase followed by induction in 2% galac-
tose for 3 hr. Cells were harvested by centrifugation (3000 RPM, 2 min)
and immediately frozen in liquid nitrogen. RNA preparation, hybridiza-
tion, image acquisition, and processing ofmicroarrayswere performed
as described (Grigull et al., 2004).
b-Galactosidase Assays
The strain ASY822 (Kafadar et al., 2003), which contains a LacZ re-
porter driven by four tandem copies of the calcineurin-dependent
response element (CDRE), was treated with 0.2% DMSO, 10 mg/ml
tamoxifen, and 50 mg/ml amiodarone for 1.5 hr, and b-galactosidase
activity was measured (Rose and Botstein, 1983).
CRZ1 Translocation Assay
An overnight culture (Y2454 + pMET-3xGFP-Crz1 [pLMB127]) in SD-
URA was diluted in SD-URA MET and grown to mid-log phase (about
5 hr). Cells were harvested and resuspended in YPD. Drug was added
to a final concentration of 10 mg/ml for tamoxifen, 50 mg/ml for amidar-
one, 19 mg/ml for amantadine hydrochloride, and 15 mg/ml clomi-
phene. One milliliter samples were spun down and examined after
10 min. Cells were visualized by epifluorescence microscopy with
a GFP filter and a 1000 ms exposure time.
Natural Product Extracts and Compound Derivation
Crude natural products were dissolved in methanol for a final stock
concentration of 10 mg/ml. Compounds were derived from natural
product extracts using methanol extraction as described (Williams
et al., 2005).
Growth Curves
From overnight YPD cultures, yeast strains Y1239, Y6883, and Y6882
were diluted to an OD600 of 0.05 in 3 ml cultures. Stichloroside (4 mg/
ml), theopaluamide (1 mg/ml), or 1%DMSOwere added to the cultures.
Cultures were incubated at 30C while shaking and ODs were re-
corded every 90min. Seven time points were taken. Each growth curve
was tested at least twice and representative curves are shown.
Generation of Resistant Mutants
Wild-type yeast BY4741a was spotted (3 ml spots of OD 1 culture) onto
YPD agar plates containing inhibitory concentrations of drug (4 mg/ml
pap B or 50 mg/ml extract 00-192). Plates were incubated for 3 to 4
days to allow resistant mutants to grow up. Resistant colonies were
confirmed by restreaking single colonies onto drug-containing media.
Seven pap B-resistant mutants were identified. Standard tetrad anal-
ysis confirmed that resistance in each strain was conferred by a reces-
sive mutation in a single gene. Six of the seven mutants were classified
into one complementation group (Pap B-R1), which was later con-
firmed as a CHO1 mutant (see below). The remaining pap B-resistant
mutant remains unidentified. Fourmutants were confirmed as resistant
to extract 00-192. Resistance was a recessive trait resulting from
mutation of a single gene in each case. Three mutants were classified
as belonging to complementation group 1 (00-192-RA) and the fourth
to complementation group 2 (00-192-RB).
Cloning of Pap B-Resistant Mutant
The pap B-resistant strain Y6531 was transformed with a high-copy
(Yep24) yeast genomic library. Transformants were selected on SD-
URA then replica-plated onto minimal media (PapB-R1 confers a
growth defect on minimal media). Plasmids were extracted from thosetransformants that grew on minimal media and inserts were se-
quenced, revealing that all plasmids contained the CHO1 gene.
Pap B Spot Assays
Yeast strains Y1239, Y7688, Y7689, Y7690, Y7691, and Y6531 were
grown overnight in YPD. Cultures were diluted in YPD to OD1. Two
microliter spots of 103 dilutions were spotted onto YPD agar plates
containing no drug, 2 mg/ml pap B, and 4 mg/ml pap B. Plates were
incubated for 2 days at 30C and photographed.
Liposome Assay
Large unilamellar vesicles (LUVs) were prepared by filter extrusion in
the presence of 5 mM calcein, a fluorescent compound that self-
quenches at high concentrations. LUVs were prepared from 100%
PC (PC), 90% PC/10% PE (PC/PE), or 90% PC/10%PS (PC/PS) and
dialyzed overnight to remove external, untrapped calcein. Leakage
of calcein from the liposomes was measured by increase in fluores-
cence (reduction of quenching upon dilution) at room temperature
in 2 ml of TNE (10 mM Tris-Cl pH 7.4, 154 mM NaCl, and 0.1 mM
EDTA) containing 50 mg LUVs. Baseline fluorescence of LUVs was
determined before Pap B addition and 100% leakage determined by
addition of Triton X-100 to 0.1% after Pap B addition.
Supplemental Data
Supplemental Data include experimental procedures, seven figures,
and nine tables and can be found with this article online at http://
www.cell.com/cgi/content/full/126/3/611/DC1/.
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